1. Introduction {#sec1}
===============

The brain is enriched with polyunsaturated fatty acids (PUFA) which make them vulnerable to attack by reactive oxygen species (ROS). ROS are by-products of normal metabolism in all aerobic cells. Most of the oxygen consumed by the cells is tetravalently reduced to water during mitochondrial respiration. Conversely, incomplete reduction of 2-3% of oxygen forms superoxide anion radical (O~2~ ^∙−^), which is highly reactive and can indiscriminately attack all cellular biomolecules in their vicinity. A sensitive balance exists between ROS production and the antioxidant defenses that protect the cells in vivo. All the same, aerobes are endowed with an orchestra of antioxidant defense enzymes like superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) and nonenzymatic antioxidant molecules like glutathione, scorbic acid, and uric acid to protect their cells from the attack of ROS such as superoxide radicals, hydrogen peroxide (H~2~O~2~), and hydroxyl radical (^∙^OH) \[[@B1]\]. In this context, it is important to note that thyroid hormones (TH) are critically involved in regulating oxygen consumption and cellular ROS production in several tissues including brain \[[@B2]--[@B4]\]. A critical role for TH in the developing brain, specifically the cerebrum and cerebellum, has been well documented \[[@B5], [@B6]\]. On the other hand, TH have a critical role in determining the cellular basal metabolic rate and oxygen consumption as well as active oxygen metabolism \[[@B7], [@B8]\]. It has been observed that a change in thyroid gland function affects production of ROS in rats \[[@B2], [@B4]\]. It has also been reported that hypothyroidism alters the antioxidant defense system in various tissues including several brain regions \[[@B9]--[@B11]\]. Peroxisome proliferator-activated receptor gamma (PPAR*γ*) as a member of superfamily of nuclear hormone receptors has been known to be important in adipocyte differentiation, lipid biosynthesis, glucose homeostasis, and immunomodulation \[[@B12], [@B13]\]. In addition, PPAR*γ* is also expressed in the central nervous system (CNS) \[[@B14], [@B15]\]. It is reported that PPAR*γ* agonists thiazolidinediones (TZDs) can provide a protective effect against CNS disorders where an inflammatory response is strongly implicated \[[@B14], [@B15]\].

It has been well documented that rosiglitazone binds with the highest affinity to PPAR*γ* \[[@B16], [@B17]\]. Our knowledge about the effects of PPAR*γ* agonists was initially limited to controlling of lipid metabolism and homeostasis. However, recent studies indicated that PPAR*γ* activation can regulate oxidative stress responses and expression of a variety of antioxidant molecules \[[@B18]\]. For instance, ligand-activated PPAR*γ* elevates expression of antioxidants including manganese SOD (MnSOD) \[[@B19], [@B20]\], GPx~3~ \[[@B21]\], the scavenger receptor CD36 \[[@B22], [@B23]\], endothelial nitric oxide synthase (eNOS) \[[@B24]\], heme-oxygenase 1 (HO-1) \[[@B25], [@B26]\], and the mitochondrial uncoupling protein 2 (UCP2) \[[@B27], [@B28]\]. Conversely, it downregulates cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) \[[@B12], [@B29], [@B30]\].

It has been reported that the activity of mitochondrial MnSOD, which oversees the dismutation of O~2~ ^∙−^ to O~2~ and H~2~O, is increased by rosiglitazone \[[@B19]\]. Moreover, in PPAR*γ* knockout mice MnSOD is downregulated at the transcriptional and translational levels with a consequent increase of O~2~ ^∙−^ levels \[[@B20]\]. In fact, promoter analysis revealed that MnSOD is a direct target of PPAR*γ* \[[@B20]\]. GPx protects the cells from oxidative stress in two ways: breaking of H~2~O~2~ to H~2~O and O (like the effect of catalase) and acting as scavenger for oxidized lipids. In addition, beneficial effects of PPAR*γ* agonists in lung \[[@B31]\], heart \[[@B32]\], kidney \[[@B33]\] and, more recently, also the brain \[[@B19], [@B29], [@B34]--[@B36]\] have been confirmed.

Thus, this study aimed to determine a protective effect of PPAR*γ* agonists on cerebellar tissues oxidative damage in hypothyroid rats.

2. Material and Methods {#sec2}
=======================

2.1. Animals and Treatments {#sec2.1}
---------------------------

Forty-nine male Wistar rats (21 days old and weighing 55--65 g) were kept in standard cages at 22 ± 2°C in a room with a 12 h light/dark cycle (light on at 7:00 am). Standard food (Javaneh Khorasan, CO, Mashhad, Iran) was available*ad libitum*.

The rats were divided into seven groups and treated as follows:Group I (control): the animals received tap drinking water.Group II (PTU): the animals received 0.05% PTU in their drinking water during 6 weeks.Group III: besides 0.05% PTU in drinking water, the animals were daily injected with 20 mg/kg vitamin (Vit E).Groups IV and V: besides 0.05% PTU in drinking water, the animals were daily injected with 10 or 20 mg/kg pioglitazone, respectively.Groups VI and VII: besides 0.05% PTU in drinking water, the animals were daily injected with 2 or 4 mg/kg rosiglitazone, respectively.

All injections were done intraperitoneally (IP). Finally, the animals were deeply anesthetized (urethane 1.4 g/kg) and the blood samples were taken to determine hypothyroidism status using the radioimmunoassay method (Diasource, T4-RIA-CT). The brains were also removed and the cerebellar tissues were separated. Then, they were made into 10% tissue homogenate in ice-cold 0.9% saline solution and were centrifuged (1000 ×g, 4°C, 10 min) to remove particulates. The obtained supernatants were aliquoted and stored at −80°C to be used for biochemical measurements.

2.2. Biochemical Assessment {#sec2.2}
---------------------------

The cerebellar tissues were analyzed for total thiol, malondialdehyde (MDA) concentrations, superoxide (SOD), catalase (CAT), and NO metabolites.

MDA levels, as an index of lipid peroxidation, were measured in the cerebellar tissues. MDA reacts with thiobarbituric acid (TBA), a thiobarbituric acid reactive substance (TBARS), and produces a red colored complex which has a peak absorbance at 535 nm. 2 ml thiobarbituric acid (TBA)/trichloroacetic acid (TCA)/hydrochloric acid (HCl) reagent was added to 1 ml homogenate and the solution was incubated in a boiling water bath for 40 min. After cooling, the whole solutions were centrifuged (1000 ×g for 10 min). The absorbance of supernatant was read at 535 nm. The MDA concentration was calculated as previously described \[[@B37], [@B38]\].

Total thiol content was measured using DTNB (2,2′-dinitro-5,5′-dithiodibenzoic acid) reagent which reacts with the SH groups and produces a yellow colored complex with a peak absorbance at 412 nm. Briefly, 1 ml Tris-EDTA (ethylenediaminetetraacetic acid) buffer (pH = 8.6) was added to 50 *μ*l brain homogenate in 1 ml cuvettes and the absorbance was read at 412 nm against Tris-EDTA buffer. Then 20 *μ*l DTNB reagent (10 mM in methanol) was added to the mixture and, after 15 min incubation in room temperature, the absorbance was read again. The absorbance of DTNB reagent was also read as a blank. Total thiol concentration was calculated based on an equation previously described \[[@B37], [@B38]\].

SOD activity was measured by the procedure described by Madesh and Balasubramanian \[[@B39]\]. This procedure is a colorimetric assay based on the generation of superoxide by pyrogallol autoxidation and the inhibition of superoxide-dependent reduction of the tetrazolium dye to its formazan by SOD. The colorimetric changes were measured at 570 nm. One unit of SOD activity was defined as the amount of enzyme causing 50% inhibition in the tetrazolium dye (MTT: (3-(4, 5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide) reduction rate \[[@B38], [@B40]\].

CAT activity was measured according to the Aebi method. The assay is done based on the rate constant, *k*, (dimension: s^−1^,  *k*) of hydrogen peroxide decomposition. By measuring the reduction in absorbance at 240 nm per minute, the rate constant of the enzyme was determined \[[@B40]\].

The Griess reaction was adapted to assay nitrates as previously described. Briefly, standard curves for nitrates were prepared and 50 *µ*l of tissue suspension was added to the Griess reagent. The proteins were subsequently precipitated by adding 50 *µ*l of 10% TCA. The contents were then mixed and centrifuged and the supernatants were pulled to a 96-well microplate. Absorbance was read at 520 nm using a microplate reader and final values were calculated from standard calibration plots \[[@B41], [@B42]\].

2.3. Statistical Analysis {#sec2.3}
-------------------------

All data were expressed as means ± SEM. Data were compared by one way ANOVA followed by LSD post hoc comparisons test. Differences were considered statistically significant when *P* \< 0.05.

3. Results {#sec3}
==========

The results showed that the rats of the PTU group had a significantly lower thyroxine concentration in their serum compared to that of control (*P* \< 0.001, [Figure 1](#fig1){ref-type="fig"}) which confirms hypothyroid status of PTU administered rats. The results also showed that Vit E and higher doses of pioglitazone and rosiglitazone improved the serum thyroxine level compared to PTU (*P* \< 0.05, *P* \< 0.01, and *P* \< 0.001, respectively, [Figure 1](#fig1){ref-type="fig"}).

Furthermore, the PTU exposure influenced MDA and thiol concentrations in the cerebellar tissues. PTU increased MDA in the cerebellar tissues compared to the control group (*P* \< 0.001, [Figure 2](#fig2){ref-type="fig"}). The results also showed that injection of Vit E and 20 mg/kg of pioglitazone prevented from increasing the MDA level by PTU (*P* \< 0.01 increasing the MDA level by PTU (*P* \< 0.01 and *P* \< 0.001, respectively, [Figure 2](#fig2){ref-type="fig"}); however, 10 mg/kg of pioglitazone was not effective in changing MDA concentrations in the cerebellar tissues of PTU treated rats ([Figure 2](#fig2){ref-type="fig"}). Additionally, both doses including 2 and 4 mg/kg rosiglitazone attenuated the MDA in the cerebellar tissues compared to PTU group (*P* \< 0.01 and *P* \< 0.001, respectively, [Figure 2](#fig2){ref-type="fig"}). The result also showed that the effects of pioglitazone and rosiglitazone were dose dependent (*P* \< 0.01--*P* \< 0.001). Additionally, both higher doses of pioglitazone and rosiglitazone were more effective than Vit E in attenuating cerebellar MDA compared to PTU (*P* \< 0.001, [Figure 2](#fig2){ref-type="fig"}).

Compared to the control group, PTU also reduced the thiol contents of the cerebellum (*P* \< 0.001, [Figure 3](#fig3){ref-type="fig"}). Treatment of the animals by Vit E resulted in an increased level of thiol contents in cerebellar tissues compared to PTU group (*P* \< 0.001, [Figure 3](#fig3){ref-type="fig"}). In addition, both doses including 10 and 20 mg/kg of pioglitazone improved thiol contents of the cerebellar tissues (both *P* \< 0.001, [Figure 3](#fig3){ref-type="fig"}). Furthermore, rosiglitazone in both doses improved the thiol contents compared to the PTU group (both *P* \< 0.001, [Figure 3](#fig3){ref-type="fig"}). Interestingly, the higher doses of both pioglitazone and rosiglitazone were significantly more effective than Vit E in increasing the thiol contents of the cerebellar tissues (both *P* \< 0.001, [Figure 3](#fig3){ref-type="fig"}). The results also showed that 20 mg/kg of pioglitazone had significantly higher effect compared to lower dose of pioglitazone to increase thiol concentration in the cerebellum (*P* \< 0.01, [Figure 3](#fig3){ref-type="fig"}). In addition, 4 mg/kg of rosiglitazone had significantly higher effect compared to lower dose of rosiglitazone (2 mg/kg) to increase thiol contents in the cerebellum (*P* \< 0.001, [Figure 3](#fig3){ref-type="fig"}).

The results also showed that PTU administration diminished the SOD activity in the cerebellum compared to control group (*P* \< 0.001, [Figure 4](#fig4){ref-type="fig"}). Treatment with Vit E significantly increased the cerebellar SOD compared to the PTU group (*P* \< 0.001, [Figure 4](#fig4){ref-type="fig"}). Additionally, treatment with both doses including 10 and 20 mg/kg of pioglitazone increased SOD activity compared to PTU (*P* \< 0.001, [Figure 4](#fig4){ref-type="fig"}). Similar to pioglitazone, treatment with both doses of rosiglitazone also improved SOD activity in the cerebellar tissues compared to the PTU group (*P* \< 0.001, [Figure 4](#fig4){ref-type="fig"}). In addition, the cerebellar tissues SOD in the hypothyroid rats treated by both doses of pioglitazone and higher dose of rosiglitazone was higher than that of Vit E (*P* \< 0.001). Compared to Vit E, 2 mg/kg rosiglitazone had a lower effect in changing SOD activity in the cerebellar tissues of hypothyroid rats (*P* \< 0.01). The results also showed that 20 mg/kg of pioglitazone had a significantly higher effect compared to lower dose of pioglitazone to increase SOD concentration in the cerebellum (*P* \< 0.01, [Figure 4](#fig4){ref-type="fig"}). In addition, 4 mg/kg of rosiglitazone had a significantly higher effect compared to lower dose of rosiglitazone (2 mg/kg) to increase SOD in the cerebellum (*P* \< 0.001, [Figure 4](#fig4){ref-type="fig"}).

Additionally, PTU exposure was associated with a significant reduction in CAT activity in the cerebellar tissues compared to control group (*P* \< 0.001, [Figure 5](#fig5){ref-type="fig"}).

Administration of Vit E and both doses including 10 and 20 mg/kg of pioglitazone inhibited the lowering effects of PTU on CAT (*P* \< 0.05--*P* \< 0.001, [Figure 5](#fig5){ref-type="fig"}). Compared to PTU group, both doses including 2 and 4 mg/kg were able to significantly increase the CAT activity in the cerebellar tissues (*P* \< 0.001, [Figure 5](#fig5){ref-type="fig"}). Interestingly both doses of pioglitazone including 10 and 20 mg/kg and both doses of rosiglitazone including 2 and 4 mg/kg were more effective than that Vit E in improving CAT in the cerebellar tissues (*P* \< 0.001, [Figure 5](#fig5){ref-type="fig"}). There was no significant difference between the low and high doses of pioglitazone and also between the two doses of pioglitazone ([Figure 5](#fig5){ref-type="fig"}).

The results showed that PTU administration increased the NO metabolites in the cerebellum (*P* \< 0.001, [Figure 6](#fig6){ref-type="fig"}). Compared to PTU group, Vit E was able to attenuate NO metabolites (*P* \< 0.001, [Figure 6](#fig6){ref-type="fig"}). Similar to Vit E, both doses of pioglitazone reduced NO metabolite concentrations (*P* \< 0.001, [Figure 6](#fig6){ref-type="fig"}). Interestingly, both doses of rosiglitazone were able to reduce NO metabolites in the cerebellum of hypothyroid rats (*P* \< 0.001, [Figure 6](#fig6){ref-type="fig"}).

4. Discussion {#sec4}
=============

The present study revealed that PPAR*γ* agonists had a protective effect on cerebellar tissues oxidative damage in juvenile hypothyroid rats. Administration of PTU has been frequently used to provide an animal model of hypothyroidism \[[@B4], [@B9]\]. It has also been demonstrated that hypothyroidism for 6 weeks brings about a decrease in tissue T~4~ concentrations in the tissue homogenates of several brain regions including cerebellum \[[@B43]\]. At the subcellular level, nuclear concentration of T~3~ has been reported to be diminished in the brain during hypothyroidism \[[@B43]\]. In the present investigation, 6-week administration of PTU significantly reduced serum T~4~ level which confirms induction of hypothyroidism in juvenile rats ([Figure 1](#fig1){ref-type="fig"}). Interestingly, we observed that high-dose rosiglitazone was able to increase T~4~. The responsible mechanism was not evaluated in the present study. It has been previously reported that rosiglitazone enhances iodine (I) uptake in the thyroid gland \[[@B44], [@B45]\] which may have a role in the results of present study.

The mechanism(s) responsible for the brain dysfunctions due to hypothyroidism seems at least in part to be due to brain tissues oxidative damage \[[@B9], [@B11]\]. In the current study, hypothyroidism decreased the antioxidant enzymes activity including SOD ([Figure 4](#fig4){ref-type="fig"}) and CAT ([Figure 5](#fig5){ref-type="fig"}) which was accompanied by an increased level of MDA ([Figure 2](#fig2){ref-type="fig"}) in the cerebellum. The total thiol contents of cerebellar tissues were also decreased ([Figure 1](#fig1){ref-type="fig"}). In support of our results, some of the studies reported that hypothyroidism conditions change the activity of the antioxidant status in several tissues including the brain \[[@B46]--[@B49]\]. Conversion of hydrogen peroxide to water and molecular oxygen is catalyzed by both CAT and GPx. However, it has been reported that H~2~O~2~ is decomposed by CAT at high concentration and by GPx at low concentration \[[@B1]\]. On the other hand, some of the studies showed that CAT activity was low in different parts of the brain homogenates of PTU treated rats \[[@B50], [@B51]\]. Deficiency of catalase has been shown to increase tissue sensitivity to oxidant injury mediated by H~2~O~2~ itself or through Fenton reaction \[[@B52]\]. Interestingly, in the current investigation, a decreased level of CAT activity was observed which may be in response to an increased level of lipid peroxidation in the cerebellum of hypothyroid rats. The enzyme SOD is considered to be the first line of cellular antioxidant defense. A decreased level in SOD activity in the hypothyroid rats might trigger increasing of O~2~ ^−^ which finally leads to increasing of lipid peroxidation. SOD is also able to scavenge O^−^ by dismutating it to H~2~O~2~ which can freely move across cell membranes and cause oxidative modification \[[@B1]\]. Regarding this evidence it seems that a decreased level of SOD and CAT has a role in increasing of lipid peroxidation which was observed in the present study after PTU administration. The results of our study are consistent with Pan et al. \[[@B53]\] who found that MDA level was elevated while SOD level was decreased in the hippocampus of hypothyroid rats. Baskol et al. \[[@B54]\] also investigated a relationship between the serum levels of MDA and SOD activity as a marker of oxidant-antioxidant system and thyroid hormone status in hypothyroidism. They showed that SOD activity was significantly higher while MDA level was lower after treatment when compared to the pretreatment of hypothyroid patients. These findings and the results of present study may suggest an imbalance between oxidant and antioxidant system as a leading factor to the brain tissues such as cerebellum oxidative damage in hypothyroidism.

Other studies \[[@B4], [@B55], [@B56]\] have also shown that hypothyroidism is associated with a decline in thiol level such as GSH in the brain. Dasgupta et al. \[[@B55], [@B56]\] reported that a reduction in specific activity of cerebral glutamate cysteine ligase and c-glutamyl transpeptidase, the key enzyme in regulation of GSH, occurs as a response to postnatal hypothyroidism. Thyroid hormone is known to play a helpful role in maintaining GSH homeostasis in astrocytes thereby protecting the brain from oxidative stress induced pathophysiological conditions \[[@B57]\].

Regarding these facts beneficial effects of the antioxidants on the brain tissues\' oxidative damage due to hypothyroidism are conceivable. Beneficial effects of Vit E as a well-known antioxidant agent on the brain tissues\' oxidative damage have been well documented \[[@B34], [@B53]\]. The antioxidant properties of PPAR*γ* agonists such as pioglitazone and rosiglitazone have been well documented \[[@B58]\]. A protection profile of PPAR*γ* agonists against tissues\' oxidative damage in an animal model of ischemia/reperfusion \[[@B34], [@B59]\] as well as in other conditions such as burns \[[@B60]\] has been reported. Considering these properties, it was assumed that rosiglitazone and pioglitazone might be effective in protecting the cerebellar tissues from oxidative damage in PTU induced hypothyroidism conditions. The results showed that, in a similar manner to Vit E, both drugs prevented from increasing of MDA in the cerebellar tissues of hypothyroid rats. To the best of our knowledge, this is the first report which shows that PPAR*γ* agonists pioglitazone and rosiglitazone are able to protect the cerebellum of juvenile hypothyroid rats from oxidative stress.

Our results showed that administration of pioglitazone or rosiglitazone in hypothyroid rat decreased cerebellar lipid peroxidation. Similarly, both drugs offered a significant improving effect on SOD and CAT activity. These data suggest that the protective effects of rosiglitazone and pioglitazone against hypothyroidism injury are partially due to their ability to reduce oxidative stress. In support of the results of present study, pioglitazone pretreatment has been shown to inhibit reactive oxygen species production in cardiac fibroblasts exposed to hypoxia/reoxygenation \[[@B61]\] and to reduce renal oxidative stress in obese rats \[[@B62]\].

Various mechanisms may involve elucidating the effects of PPAR*γ* agonists on oxidative stress parameters in the cerebellum of the rats. First, it has been well documented that activation of PPAR*γ* has beneficial effects on expression of antioxidant enzymes including SOD, GPx~3~, and CAT \[[@B58], [@B63]\]. An increased level of the antioxidant enzymes activities including CAT and SOD by PPAR*γ* agonists has also been reported \[[@B64]\]. Therefore, an increased level of CAT and SOD activities may be responsible for the beneficial effects of rosiglitazone or pioglitazone which were observed in the present study. Second, mitochondria are the major source of reactive oxygen species, which are mainly generated at complexes I and III of the respiratory chain \[[@B65]\]. There is now evidence that PPAR*γ* agonists exert direct and rapid effects on mitochondrial respiration, inhibiting complex I \[[@B66]\] and complex III \[[@B67]\] activities. As PPAR*γ* agonists partially disrupt the mitochondrial respiratory chain, both electron transport and superoxide anion generation are affected. Moreover, a novel mitochondrial target protein for PPAR*γ* agonists ("mitoNEET") has recently been identified \[[@B68]\]. MitoNEET was found to be associated with components of complex III, suggesting how PPAR*γ* agonists binding to mitoNEET could selectively block different mitochondrial targets. Third, in addition, it has been demonstrated that PPAR*γ* agonists are able to inhibit mitochondrial pyruvate carrier (MPC) \[[@B69]\]. Therefore, a reduction in intramitochondrial pyruvate level would be able to stimulate mitochondrial malic enzyme activity; the alter produces pyruvate from malate and then increases NAD(P)H levels. An increased level in NAD(P)H is able to elevate GSH production. Therefore, MPC inhibition may decrease free radical levels by enhancing GSH levels. Taking into account these findings, PPAR*γ* agonists\' ability to influence mitochondrial function might be attributed to their inhibitory effects on reactive oxygen species generation evoked by hypothyroidism.

Another important molecule involved in the oxidative pathway leading to cell damage is nitric oxide (NO). Under pathological conditions, NO possibly promotes oxidative damage, through the formation of a highly reactive metabolite peroxynitrite \[[@B70], [@B71]\]. A relationship between thyroid hormones and the NO system has been confirmed \[[@B72]--[@B74]\]. Many studies showed that thyroid hormones act as regulating of NO synthase gene expression in the brain \[[@B41], [@B75], [@B76]\]. It is also suggested that hypothyroidism increases nNOS activity and NO in amygdala and hippocampus \[[@B41], [@B75]\]. On the one hand, under pathological conditions, NO reacts with superoxide and produces peroxynitrite, a powerful oxidant, which is able to damage many biological molecules \[[@B70], [@B71], [@B77]\]. Moreover, NO induces a mitochondrial dysfunction due to damaging of the complexes of respiratory chain, (complexes I-III, II-III, and cytochrome c oxidase) which finally lead to a more formed superoxide radicals \[[@B2], [@B78]\]. In the present study, both PPAR*γ* agonists reduced NO metabolites which might be considered as another mechanism(s) responsible for their beneficial effects.

In conclusion, the results of present study showed for the first time that the PPAR*γ* agonists rosiglitazone and pioglitazone exert protective effects against cerebellar injury in hypothyroidism by protecting against tissues\' oxidative damage.
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